In stage 1, 60 FTD patients would receive three different dose schedules of 72 IU intranasal oxytocin (i.e., daily, alternate days, or every third day dosing) or placebo in order to identify the most promising dose scheduling; then, after a 6-week washout, patients would receive for 6 weeks the alternate drug (placebo or oxytocin). This evidence concerns the gene OXT and frontotemporal dementia.